Modality
ERT
MOA
WEE1i
Target
FXIa
Pathway
RAS/MAPK
Heart FailureLGS
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Dec 2030
Phase 2Current
NCT08702058
1,804 pts·Heart Failure
2018-02→2030-12·Active
NCT05939041
2,548 pts·LGS
2024-08→2026-02·Not yet recruiting
4,352 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-161mo agoPh3 Readout· LGS
2030-12-204.7y awayPh3 Readout· Heart Failure
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-02-16 · 1mo ago
LGS
Ph3 Readout
2030-12-20 · 4.7y away
Heart Failure
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08702058 | Phase 2/3 | Heart Failure | Active | 1804 | DOR |
| NCT05939041 | Phase 2/3 | LGS | Not yet recr... | 2548 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |